Meeting News
Meeting News
Advertisement
Eric Winer, MDAcute Myeloid Leukemia | June 21, 2024
Drs. Winer, Daver, and Abaza discuss the major breakthroughs in the treatment of acute myeloid leukemia.
View More
Eric Winer, MDAcute Myeloid Leukemia | June 17, 2024
Drs. Winer, Abaza, and Daver discuss their own treatment strategies for patients with AML.
Manali Kamdar, MDMeeting News | June 6, 2024
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
Catherine Coombs, MDChronic Lymphocytic Leukemia | April 19, 2024
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Edward Cliff, MDBlood Cancer Talks | April 11, 2024
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
Cecilia BrownIndolent B-Cell Lymphoma | March 8, 2024
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Advertisement
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Patrick DalyChronic Lymphocytic Leukemia | February 21, 2024
Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up.
Paula Rodríguez Otero, MDMyeloma | February 15, 2024
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Leyla Shune, MDMyeloma | January 5, 2024
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Rafael Fonseca, MDMyeloma | January 4, 2024
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.
Patrick DalyMyeloma | December 20, 2023
Elranatamab yielded deep and durable responses in relapsed or refractory multiple myeloma, even with biweekly dosing.
Patrick DalyMyeloma | December 20, 2023
Dara-CVRd was effective as induction therapy prior to and consolidation therapy following AHSCT in ultra-high-risk myeloma.
Patrick DalyMyeloma | December 20, 2023
Motixafortide plus G-CSF mobilized significantly more CD34+ hematopoietic stem and progenitor cells versus placebo in MM.
Leah SherwoodMeeting News | December 18, 2023
DDX3X dysregulation is involved in the progression of CLL by facilitating NOTCH1 mRNA translation
Leah SherwoodMeeting News | December 18, 2023
Researchers said there was a need for potentially more effective one-time-only treatment options.
Hans Lee, MDMyeloma | December 19, 2023
Dr. Hans Lee met with Blood Cancers Today to discuss outcomes and treatments after triple-class exposure in multiple myeloma.
Patrick DalyIndolent B-Cell Lymphoma | February 16, 2024
It included 21 patients with lymphoma with a median age of 57 who had received a median of four prior lines of therapy.
Noopur Raje, MDMyeloma | December 18, 2023
Dr. Raje shared findings on CAR T-cell therapy in earlier lines of treatment for relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | December 15, 2023
Patients with lenalidomide-refractory MM had significant improvements in health-related QoL and symptoms after cilta-cel.
Advertisement
Advertisement
Editorial Board